• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Ventures – Embracing autumn with exciting updates and amazing achievements!
Oct 12 2023

Whilst Jeremy Hunt says he has no leeway to cut UK taxes at present, we at o2h Ventures are seeing a surge in investment opportunities from early-stage UK biotech. It feels like we are at the beginning of the next investment cycle and given the overall investment appetite and our growing presence; we have a large number of investment options coupled with more realistic valuations.

We are thrilled to announce the launch of our latest investment opportunity, the Knowledge-intensive EIS Fund VI which is open for investment till 31st October 2023, and we believe this is the perfect time for our valued investors to be part of an exhilarating biotech portfolio. We aim to fully deploy our funds within a 12-month time frame in 5-10 biotech companies most of which will be de-risked follow-on investment in the most exciting companies in the existing portfolio. Check out our existing portfolio here.

o2h Ventures Awards and Recognition

Celebrating Hat-trick of Awards! – We are thrilled to announce that we have been selected as finalists in three prestigious awards this year in all three different categories.

UKBAA Awards: Finalist for the Best Regional Manager category. 

EISA Awards: Finalist for the prestigious EIS Impact Award 2023.

Growth Investor Awards: Finalists for the Best EIS Investment Manager – Specialist category (results coming soon)

Read this article on Powering regional growth – the Cambridge cluster in collaboration with Intelligent Partnership 

If you are interested in gaining valuable insights into biotech investing, tax-efficient investment strategies, and the future of the industry, do not miss our CEO, Sunil Shah’s latest article HERE.

Powering Regional Growth - the Cambridge Cluster by Sunil Shah

Furthermore, if you wish to delve deep into the world of biotech investing, tune into this episode of the EIS Navigator Podcast – Biotech Update and Investing. Listen to the podcast here – click here.

Deals executed:

Pencil Biosciences (Alderly Park, Manchester): specializing in gene editing and modulation technology, successfully secured seed funding of £5.6M raise, o2h Ventures co-invested with Octopus Investments and Northen Gritstone. o2h Ventures had also earlier invested into the Pre-Seed round. To read more about it, click here. 

Some key portfolio highlights: 

  • Kuano, a pioneering drug discovery company, has successfully concluded its seed funding round, securing a substantial £1.8 million. Kuano distinguishes itself through its innovative fusion of quantum mechanics and artificial intelligence in the pursuit of next-generation medicines. o2h Ventures had also earlier invested into the PreSeed round and provided Board level support. 
  • Cybin set to acquire Small Pharma U.K.-based biotechnology company focused on short-duration psychedelic therapies for mental health conditions.
  • Heartfelt Technologies won the prestigious Santander X Global Challenge | The AI Revolution, organised by Santander, Microsoft and Oxentia Foundation. Heartfelt Technologies is dedicated to supporting patients, their families, carers and doctors, to reduce hospital readmission rates from heart failure decompensation.

Meet us at Cambridge – Ready Steady Grow, a knowledge share and networking event managed by the EISA, that will provide attendees updates on funding options and the latest developments in the Enterprise Investment Scheme (EIS) and SEIS industry. Register here.

Event by EIS Association in Cambridge

Check out this Hardman report on knowledge-intensive EIS fund

Take a look at the comprehensive Tax Enhanced Research published by Hardman & Co about the o2h Human Health EIS Knowledge-Intensive Fund. With a vast team of investment professionals and market analysts, Hardman & Co provides unparalleled insights into tax-enhanced products. Download from here.

Connect with us
  • linkedin
  • youtube
  • email
o2h-ventures
related stories
  • o2h Ventures Recognised at EISA Impact Awards 2025 for Exonate’s Topical Eye-Drop for Diabetic Retinopathy 20 June, 2025
  • o2h Ventures Shortlisted for Two EISA Awards 2025: Impact and Ecosystem Champion 31 May, 2025
  • o2h Ventures Makes SEIS investment in Sansanima, A University of Sheffield Spinout Developing Alternatives to Animal Testing 28 May, 2025
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)